Skip to main content Skip to navigation


Tackling Early Morbidity and Mortality in Myeloma:


Assessing the benefit of antibiotic prophylaxis and it's effect on healthcare asscoiated infection




A randomised, multicentre, double blind, placebo-controlled trial


myeloma logounibhamHTACTU logo


TEAMM is funded by the NIHR HTA and lead by professor Mark Drayson at the University of Birmimgham in conjunction with the University of Warwick Clinical Trials Unit